Insulin Resistance: The Driving Force behind the Metabolic Syndrome


Activity Description

CME Release Date: April 4, 2011
CME Expiration Date: April 4, 2012

Statement of Need

It is well-known that patients with diabetes and the cardiometabolic syndrome are at increased risk for developing cardiovascular disease. With the increase in prevalence of the cardiometabolic syndrome and its comorbidities, the need to optimize preventive and therapeutic interventions is a major focus of most clinicians in primary care. Clinicians must recognize the signs of the cardiometabolic syndrome in order to initiate early and effective preventive interventions to reduce eventual morbidity and mortality.

Diabetes and the Heart 2010: A Clinical Summit on Critically Challenging Patients was the second annual summit of the Joslin Diabetes Center and Cleveland Clinic partnership. Among the largest and most respected academic providers of CME, our two institutions believe that the greatest reach and impact can be achieved in continuing medical education through innovative collaboration. With world-class clinical care protocols and cutting-edge knowledge in both diabetes and cardiac care, we feel that together, we will engage the largest audience more efficiently and effectively.


This Internet enduring material was developed from the State of the Science Address titled Insulin Resistance: The Driving Force behind the Metabolic Syndrome, delivered by Dr. C. Ronald Kahn on September 13, 2010 at the Diabetes and the Heart 2010 summit in Boston, MA. This address focused on recent research in the cellular and molecular basis of diabetes and Metabolic Syndrome.

Target Audience

This certified activity was developed for primary care providers with a practice population that includes significant numbers of people with diabetes, other components of the cardiometabolic syndrome, and/or cardiovascular disease; also cardiologists, diabetologists, and lipidologists.

Learning Objectives

After participating in this educational activity healthcare professionals should be able to:
  1. Describe the pathologic mechanisms of insulin resistance and the metabolic syndrome.
  2. Explain the mechanisms of insulin resistance in the liver and how they impact glycemic control.
  3. Describe the phenotype of dyslipidemia seen in insulin resistance and the metabolic syndrome.
  4. Summarize the potential mechanisms by which mitochondrial dysfunction contribute to insulin resistance and metabolic syndrome.

Faculty and Disclosures

C. Ronald Kahn, MD
Mary K. Iacocca Professor
Harvard Medical School and Joslin Diabetes Center
Boston, MA

Disclosure: Dr. C. Ronald Kahn is a consultant for Dicerna, FivePrime Therapeutics, Plexxikon, and Sirtris Pharmaceuticals, and receives grant/research support from Eli Lilly and Company.

Planning Committee:

Julie A. Brown*
Director
Professional Education
Joslin Diabetes Center
Boston, MA

Disclosure: Ms Brown has no relevant financial relationships.

Richard S. Beaser, MD*
Medical Executive Director
Professional Education
Joslin Diabetes Center
Boston, MA

Disclosure: Dr Beaser is a consultant for CeQur Ltd.

James Neighbours, MEd*
Assistant Director
Educational Design and Outcomes
Professional Education
Joslin Diabetes Center
Boston, MA

Disclosure: Mr Neighbours has no relevant financial relationships.

Karen J. Kuc, MPH*
Assistant Director, Grants and Projects
Professional Education
Joslin Diabetes Center
Boston, MA

Disclosure: Ms Kuc has no relevant financial relationships.

Jonathan B. Scoble*
Grants Manager
Professional Education
Joslin Diabetes Center
Boston, MA

Disclosure: Mr Scoble has no relevant financial relationships.

Kenneth J. Snow, MD
Associate Medical Director
Professional Education Department
Joslin Diabetes Center
Boston, MA

Disclosure: Dr. Snow has no relevant financial relationships.

*Also on the CME Advisory Committee

CME Advisory Committee:

Enrique Caballero, MD
Director, Medical Affairs
Professional Education
Director, Latino Diabetes Initiative
Joslin Diabetes Center
Boston, MA

Disclosure: Dr. Enrique Caballero is a consultant and on the speakers bureau and scientific advisory board for Amylin Pharmaceuticals, Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., and Eli Lilly and Company.

Jerry Cavallerano, OD, PhD
Optometrist
Beetham Eye Institute
Joslin Diabetes Center
Boston, MA

Disclosure: Dr. Jerry Cavallerano has no relevant financial relationships.

A. Patrick Egan, MD
Family Practice
Internal Medicine Specialist
Dorchester House Multi-Service Center
Boston, MA

Disclosure: Dr. A. Patrick Egan has no relevant financial relationships.

Ann E. Goebel-Fabbri, PhD
Instructor in Psychiatry
Harvard Medical School
Psychologist
Behavioral and Mental Health Unit
Joslin Diabetes Center
Boston, MA

Disclosure: Anne E. Goebel-Fabbri has no relevant financial relationships.

Osama Hamdy, MD, PhD, FACE
Assistant Professor of Medicine
Harvard Medical School
Medical Director, Obesity Clinical Program
Joslin Diabetes Center
Boston, MA

Disclosure: Dr. Osama Hamdy is on the speakers bureau for Amylin Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., Novo Nordisk Inc., and Takeda Pharmaceuticals North America, Inc.

Eyiuche Okeke, MD
Instructor in Medicine
Harvard Medical School
Outcomes Investigator
Department of Professional Education
Staff Endocrinologist
Joslin Diabetes Center
Boston, MA

Disclosure: Dr. Euyiche Okeke has no relevant financial relationships.

Robert C. Stanton, MD
Associate Professor of Medicine
Harvard Medical School
Chief of Nephrology
Joslin Diabetes Center
Boston, MA

Disclosure: Dr. Robert C. Stanton has no relevant financial relationships.

Howard Wolpert, MD
Assistant Professor of Medicine
Harvard Medical School
Director, Insulin Pump Program
Senior Physician
Joslin Diabetes Center
Boston, MA

Dr. Howard A. Wolpert is a consultant for Abbott Diabetes Care, Insulet Corporation, Novo Nordisk, Inc. and Becton, Dickinson and Company.

Accreditation and Designation of Credit

Joslin Diabetes Center, Boston, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians. The Joslin Diabetes Center designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

This CME activity was planned and produced in accordance with ACCME Essentials.
Participants not eligible for CME credit will receive a certificate of participation

Computer Requirements

To participate in this activity, your computer will need the following hardware and software:

PC Users:
Macintosh Users System OS X:
Credit Instructions
  1. Read the learning objectives, accreditation information, and faculty disclosures at the beginning of the activity.
  2. Click on the link below to register for the activity.
  3. After registering, click on the link to enter the Webcast and view the online video and slides. Click on the controls above the slide to manually advance the slides.
  4. Complete the online evaluation.
  5. Physicians who view the Webcast and complete the evaluation will receive a CME certificate as a PDF sent to their email address.
  6. All other participants who view the Webcast and complete the evaluation will receive a certificate of participation as a PDF sent to their email address.

For questions regarding the content of this activity, contact the accredited provider for this CME activity: cme@joslin.harvard.edu.

 
Register for the Webcast